Abstract
The COVID-19 pandemic has led to unprecedented challenges in Alzheimer’s disease and related dementias (ADRD) clinical trials research. Scientists continue to grapple with the potential and multifaceted consequences of COVID-19. This presentation will discuss strategies used at a U.S. Alzheimer’s Disease Research Center to implement virtual methods to counter COVID-19’s impact on safety for continued research engagement; address the disparate impact by age, race, and ethnicity for online accessibility; and plans for virtual engagement in future research. As scientists navigate lasting implications of COVID-19, future study planning, design, and management will likely be altered. Specifically, increased awareness of participant-centered approaches, inclusion of psychosocial implications, and focus on ways to meet older adults’ unique needs of virtual accessibility will be needed. We must be intentional to counter COVID-19’s lasting impact on ADRD clinical trials research while maintaining rigor and reproducibility to uphold and progress advances toward treatment and cures for ADRD.
Perspective on race and ethnicity in Alzheimer's disease research
